Patents Assigned to Pharis Biotech GmbH
  • CXC chemokine receptor 4 (CXCR4) antagonistic polypeptide
    Patent number: 9045563
    Abstract: A peptide having the following amino acid sequence: Z1-LVRYTKKVPQVSTPTL-Z2(ALB-408) and its biologically active fragments and/or variants and/or derivatives, especially amidated, acetylated, sulfated, phosphorylated and/or glycosylated derivatives, and peptides obtainable by multiple synthesis which have the biological activity of ALB408-423; wherein Z represents number of from 0 to 10 amino acid residues.
    Type: Grant
    Filed: July 3, 2008
    Date of Patent: June 2, 2015
    Assignee: PHARIS BIOTECH GMBH
    Inventors: Wolf-Georg Forssmann, Frank Kirchhoff, Jan Münch, Ludger Ständker
  • Use of natriuretic peptides for treating angioedema syndromes
    Patent number: 8293711
    Abstract: The present invention relates to the use of a natriuretic peptide, urodilatin, for treating patients suffering from acute drug induced angioedema, such as ACE inhibitor related adverse events. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously for 18 hours to 72 hours.
    Type: Grant
    Filed: September 11, 2008
    Date of Patent: October 23, 2012
    Assignee: Pharis Biotech GmbH
    Inventor: Wolf-Georg Forssmann